Marrone Laura, Romano Simona, Malasomma Chiara, Di Giacomo Valeria, Cerullo Andrea, Abate Rosetta, Vecchione Marialuisa Alessandra, Fratantonio Deborah, Romano Maria Fiammetta
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Department of Medicine and Surgery, LUM University Giuseppe Degennaro, Bari, Italy.
Front Pharmacol. 2024 Apr 10;15:1375993. doi: 10.3389/fphar.2024.1375993. eCollection 2024.
Cancer stem cells (CSC) are the leading cause of the failure of anti-tumor treatments. These aggressive cancer cells are preserved and sustained by adjacent cells forming a specialized microenvironment, termed niche, among which tumor-associated macrophages (TAMs) are critical players. The cycle of tricarboxylic acids, fatty acid oxidation path, and electron transport chain have been proven to play central roles in the development and maintenance of CSCs and TAMs. By improving their oxidative metabolism, cancer cells are able to extract more energy from nutrients, which allows them to survive in nutritionally defective environments. Because mitochondria are crucial bioenergetic hubs and sites of these metabolic pathways, major hopes are posed for drugs targeting mitochondria. A wide range of medications targeting mitochondria, electron transport chain complexes, or oxidative enzymes are currently investigated in phase 1 and phase 2 clinical trials against hard-to-treat tumors. This review article aims to highlight recent literature on the metabolic adaptations of CSCs and their supporting macrophages. A focus is provided on the resistance and dormancy behaviors that give CSCs a selection advantage and quiescence capacity in particularly hostile microenvironments and the role of TAMs in supporting these attitudes. The article also describes medicaments that have demonstrated a robust ability to disrupt core oxidative metabolism in preclinical cancer studies and are currently being tested in clinical trials.
癌症干细胞(CSC)是抗肿瘤治疗失败的主要原因。这些侵袭性癌细胞由形成特殊微环境(称为龛位)的相邻细胞保存和维持,其中肿瘤相关巨噬细胞(TAM)是关键参与者。三羧酸循环、脂肪酸氧化途径和电子传递链已被证明在癌症干细胞和肿瘤相关巨噬细胞的发育和维持中起核心作用。通过改善其氧化代谢,癌细胞能够从营养物质中提取更多能量,这使它们能够在营养缺陷的环境中存活。由于线粒体是这些代谢途径的关键生物能量枢纽和场所,因此针对线粒体的药物带来了很大希望。目前,针对线粒体、电子传递链复合物或氧化酶的多种药物正在针对难治性肿瘤进行1期和2期临床试验研究。这篇综述文章旨在强调关于癌症干细胞及其支持性巨噬细胞代谢适应性的最新文献。重点关注赋予癌症干细胞在特别恶劣的微环境中选择优势和静止能力的抗性和休眠行为,以及肿瘤相关巨噬细胞在支持这些状态中的作用。文章还描述了在临床前癌症研究中已证明具有强大破坏核心氧化代谢能力且目前正在临床试验中进行测试的药物。